De-escalation of the adjuvant radiotherapy doses in patients with HPV-related oropharyngeal tumors with high levels of CD8+ tumor infiltrating lymphocytes: a multicentre, randomized, controlled clinical trial
Full Text
Share
BACKGROUND: New epidemiological data indicate that the incidence of oropharyngeal
squamous cell carcinomas (OPSCC) is rapidly increasing due to human papillomavirus (HPV).
Patients that suffer from a HPV-related OPSCC present distinct characteristics such as younger
age, early T-stage but more advanced N-stage, absence of tobacco and alcohol as risk factors,
but, more importantly, a significantly better prognosis. Despite their better outcome, these
patients are still being treated with the same protocols as not HPV-related tumors and thus, are
exposed to the same toxicity and the potentially unnecessary side-effects should not be
underestimated. Several protocols of treatment de-escalation are under study in subgroups of
patients with different characteristics. In the current study, we will address patients with the
best prognosis in order to limit the possibility of negatively affecting the oncologic control. For
this purpose we will, incorporate CD8+ tumor infiltrating lymphocytes (TILs) as an additional
inclusion criteria.
OBJECTIVES: The aim of this study is to prove that de-escalation of the radiotherapeutic
adjuvant treatment in patients with HPV-related OPSCC in early stages and displaying additional
good prognosis factors, is non-inferior in terms of overall survival. As secondary outcomes we
will address local recurrence and post-treatment swallowing dysfunction.
DESIGN AND SETTING: This is designed as a multicentre, randomized, open-labelled non-
inferiority clinical trial. It will be performed among four tertiary hospitals of Catalonia.
PARTICIPANTS: patients aged between 18 and 60 years, with HPV-related OPSCC that have high
numbers of CD8+ TILs, are tributary to transoral robotic surgery and have a T-stage <3 and N-
stage <N2c.
METHODS:
• Participants will be recruited consecutively and aim at 260 patients.
• We will assign randomly patients to two treatment groups: standard adjuvant treatment (A)
and de-escalated treatment (B) while stratifying by the type of adjuvant treatment required
(radio or chemo-radiotherapy) (N=65 patients in each subgroup).
• The de-escalation strategy will consist on reducing the protocol of adjuvant radiotherapy in
10 Gy. A follow-up of 5 years will be performed.
• Cox hazard ratio will be used for the statistical analyses, in which a confidence interval of
95% will be calculated and significance is defined as a bilateral p<0.05